Top

Published in:

01-02-2012 | ANTIPHOSPHOLIPID SYNDROME (RAS ROUBEY, SECTION EDITOR)

Management of Obstetric Antiphospholipid Syndrome

Authors: Guilherme Ribeiro Ramires de Jesus, Flavia Cunha dos Santos, Camila Souto Oliveira, Wallace Mendes-Silva, Nilson Ramires de Jesus, Roger Abramino Levy

Published in: Current Rheumatology Reports | Issue 1/2012

Abstract

Recurrent early miscarriages (excluding chromosomal anomalies), late fetal loss, and maternal thrombosis are characteristic of obstetric antiphospholipid syndrome (APS). Obstetric complications such as preeclampsia, fetal growth restriction, premature delivery, and fetal death also occur in higher frequency in APS patients than in the general population. A high-risk obstetric center is needed for proper evaluation of and intervention with pregnant women with APS. Association with lupus carries additional risk of thrombosis when antiphospholipid antibodies (aPLs) are present. Gestational results with live births are improved to about 80% when antithrombotic therapy is used, but failure in 20% to 30% of the cases despite correct treatment with low-dose aspirin with or without heparin reveals new pathways for pregnancy loss in APS and unmet needs. At the moment, there is no recommendation to investigate patients with infertility for the presence of aPLs.

•• Levy RA, Jesus GR, Jesus NR. Obstetric antiphospholipid syndrome: still a challenge. Lupus. 2010;19(4):457–9. This recent review updates the center experience with the use of warfarin from 14 to 36 weeks of pregnancy. It focuses on obstetric APS, discussing follow-up, controversies regarding treatment, management postpartum, and counseling of this group of patients.PubMedCrossRef

Ruiz-Irastorza G, Khamashta MA. Antiphospholipid syndrome in pregnancy. Rheum Dis Clin North Am. 2007;33(2):287–97. vi.PubMedCrossRef

Opatrny L, David M, Kahn SR, et al. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol. 2006;33(11):2214–21.PubMed

• Tuthill JI, Khamashta MA. Management of antiphospholipid syndrome. J Autoimmun. 2009;33(2):92–8. This is an excellent review of risks, treatment, and management of APS, with a simple chart focusing on management during pregnancy.PubMedCrossRef

• Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376(9751):1498–509. This is a broad review of the pathogenesis, clinical manifestations, and treatment of clinical APS, with a smaller but objective orientation toward treatment of obstetric APS.PubMedCrossRef

•• Heilmann L, Schorsch M, Hahn T, Fareed J. Antiphospholipid syndrome and pre-eclampsia. Semin Thromb Hemost. 2011;37(2):141–5. This recent study showed that 20% of patients with severe preeclampsia before 34 weeks of pregnancy are aPL positive and suggests investigation for APS in all patients in this group.PubMedCrossRef

• Serrano F, Nogueira I, Borges A, Branco J. Primary antiphospholipid syndrome: pregnancy outcome in a portuguese population. Acta Reumatol Port. 2009;34(3):492–7. This was a study of 67 pregnancies in 51 APS patients in a Portuguese population showing a higher incidence of cesarean section delivery, fetal growth restriction, and hypertensive disorders in this group of patients.PubMed

•• Bramham K, Hunt BJ, Germain S, et al. Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus. 2010;19(1):58–64. This interesting work compared the gestational results in three clinical presentations of APS (REM, late fetal loss, and maternal thrombosis), showing that patients with a history of thrombosis have a higher incidence of obstetric complications than the other two groups.PubMedCrossRef

Le Thi Huong D, Wechsler B, Vauthier-Brouzes D, et al. The second trimester Doppler ultrasound examination is the best predictor of late pregnancy outcome in systemic lupus erythematosus and/or the antiphospholipid syndrome. Rheumatology (Oxford). 2006;45(3):332–8.CrossRef

10.

Carp HJ, Shoenfeld Y. Recurrent spontaneous abortions in antiphospholipid syndrome: natural killer cells—an additional mechanism in a multi factorial process. Rheumatology (Oxford). 2007;46(10):1517–9.CrossRef

11.

Hornstein MD, Davis OK, Massey JB, et al. Antiphospholipid antibodies and in vitro fertilization success: a meta-analysis. Fertil Steril. 2000;73(2):330–3.PubMedCrossRef

12.

Sher G, Fisch JD, Maassarani G, et al. Antibodies to phosphatidylethanolamine and phosphatidylserine are associated with increased natural killer cell activity in non-male factor infertility patients. Hum Reprod. 2000;15(9):1932–6.PubMedCrossRef

13.

Kaider AS, Kaider BD, Janowicz PB, Roussev RG. Immunodiagnostic evaluation in women with reproductive failure. Am J Reprod Immunol. 1999;42(6):335–46.PubMedCrossRef

14.

Yinon Y, Pauzner R, Dulitzky M, et al. Safety of IVF under anticoagulant therapy in patients at risk for thrombo-embolic events. Reprod Biomed Online. 2006;12(3):354–8.PubMedCrossRef

15.

Guballa N, Sammaritano L, Schwartzman S, et al. Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum. 2000;43(3):550–6.PubMedCrossRef

16.

Le Thi Huong D, Wechsler B, Piette JC. Ovulation induction therapy and systemic lupus erythematosus. Ann Med Interne (Paris). 2003;154(1):45–50.

17.

•• Bellver J, Pellicer A. Ovarian stimulation for ovulation induction and in vitro fertilization in patients with systemic lupus erythematosus and antiphospholipid syndrome. Fertil Steril. 2009;92(6):1803–10. This is a good review considering all aspects (pathogenesis, treatment) of SLE and the role of APS/aPLs in infertility patients. It also provides an orientation regarding how these patients should be managed when ovulation induction and in vitro fertilization are used.PubMedCrossRef

18.

Udoff LC, Branch DW. Management of patients with antiphospholipid antibodies undergoing in vitro fertilization. J Autoimmun. 2000;15(2):209–11.PubMedCrossRef

19.

Sebire NJ, Fox H, Backos M, et al. Defective endovascular trophoblast invasion in primary antiphospholipid antibody syndrome-associated early pregnancy failure. Hum Reprod. 2002;17(4):1067–71.PubMedCrossRef

20.

Magid MS, Kaplan C, Sammaritano LR, et al. Placental pathology in systemic lupus erythematosus: a prospective study. Am J Obstet Gynecol. 1998;179(1):226–34.PubMedCrossRef

21.

Van Horn JT, Craven C, Ward K, et al. Histologic features of placentas and abortion specimens from women with antiphospholipid and antiphospholipid-like syndromes. Placenta. 2004;25(7):642–8.PubMedCrossRef

22.

Bose P, Kadyrov M, Goldin R, et al. Aberrations of early trophoblast differentiation predispose to pregnancy failure: lessons from the anti-phospholipid syndrome. Placenta. 2006;27(8):869–75.PubMedCrossRef

23.

Stone S, Pijnenborg R, Vercruysse L, et al. The placental bed in pregnancies complicated by primary antiphospholipid syndrome. Placenta. 2006;27(4–5):457–67.PubMedCrossRef

24.

Adams M. Novel considerations in the pathogenesis of the antiphospholipid syndrome: involvement of the tissue factor pathway of blood coagulation. Semin Thromb Hemost. 2008;34(3):251–5.PubMedCrossRef

25.

Backos M, Rai R, Thomas E, et al. Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Hum Reprod. 1999;14(11):2876–80.PubMedCrossRef

26.

Branch DW, Khamashta MA. Antiphospholipid syndrome: obstetric diagnosis, management, and controversies. Obstet Gynecol. 2003;101(6):1333–44.PubMedCrossRef

27.

Triolo G, Ferrante A, Ciccia F, et al. Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies. Arthritis Rheum. 2003;48(3):728–31.PubMedCrossRef

28.

Carmona F, Font J, Azulay M, et al. Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis. Am J Reprod Immunol. 2001;46(4):274–9.PubMedCrossRef

29.

Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol. 1996;174(5):1584–9.PubMedCrossRef

30.

Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997;314(7076):253–7.PubMedCrossRef

31.

Stephenson MD, Ballem PJ, Tsang P, et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin. J Obstet Gynaecol Can. 2004;26(8):729–34.PubMed

32.

Noble LS, Kutteh WH, Lashey N, et al. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin. Fertil Steril. 2005;83(3):684–90.PubMedCrossRef

33.

Silver RK, MacGregor SN, Sholl JS, et al. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol. 1993;169(6):1411–7.PubMed

34.

Lima F, Khamashta MA, Buchanan NM, et al. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol. 1996;14(2):131–6.PubMed

35.

Granger KA, Farquharson RG. Obstetric outcome in antiphospholipid syndrome. Lupus. 1997;6(6):509–13.PubMedCrossRef

36.

Munoz-Rodriguez FJ, Font J, Cervera R, et al. Clinical study and follow-up of 100 patients with the antiphospholipid syndrome. Semin Arthritis Rheum. 1999;29(3):182–90.PubMedCrossRef

37.

Pattison NS, Chamley LW, Birdsall M, et al. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol. 2000;183(4):1008–12.PubMedCrossRef

38.

Huong DL, Wechsler B, Bletry O, et al. A study of 75 pregnancies in patients with antiphospholipid syndrome. J Rheumatol. 2001;28(9):2025–30.PubMed

39.

Empson M, Lassere M, Craig J, Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005;2:CD002859.PubMed

40.

Cowchock FS, Reece EA, Balaban D, et al. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am J Obstet Gynecol. 1992;166(5):1318–23.PubMed

41.

Branch DW, Peaceman AM, Druzin M, et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. Am J Obstet Gynecol. 2000;182(1 Pt 1):122–7.PubMedCrossRef

42.

Vaquero E, Lazzarin N, Valensise H, et al. Pregnancy outcome in recurrent spontaneous abortion associated with antiphospholipid antibodies: a comparative study of intravenous immunoglobulin versus prednisone plus low-dose aspirin. Am J Reprod Immunol. 2001;45(3):174–9.PubMedCrossRef

43.

Holers VM, Girardi G, Mo L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med. 2002;195(2):211–20.PubMedCrossRef

44.

Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004;10(11):1222–6.PubMedCrossRef

45.

Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol. 2002;100(3):408–13.PubMedCrossRef

46.

Petri M, Qazi U. Management of antiphospholipid syndrome in pregnancy. Rheum Dis Clin North Am. 2006;32(3):591–607.PubMedCrossRef

47.

Pauzner R, Dulitzki M, Langevitz P, et al. Low molecular weight heparin and warfarin in the treatment of patients with antiphospholipid syndrome during pregnancy. Thromb Haemost. 2001;86(6):1379–84.PubMed

48.

•• Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011;20(2):206–18. This article has the latest evidence-based recommendations for treatment of nonobstetric patients with APS, which were discussed on the XIIIth International APS Congress held in Galveston, TX.PubMedCrossRef

49.

Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992;117(4):303–8.PubMed

50.

Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332(15):993–7.PubMedCrossRef

51.

Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007;57(8):1487–95.PubMedCrossRef

52.

•• Giles I, Rahman A. How to manage patients with systemic lupus erythematosus who are also antiphospholipid antibody positive. Best Pract Res Clin Rheumatol. 2009;23(4):525–37. This article emphasizes specific aspects of patients with SLE who are positive for aPLs and how to manage them.PubMedCrossRef

53.

Levy RA, Vilela VS, Cataldo MJ, et al. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus. 2001;10(6):401–4.PubMedCrossRef

54.

• Keeling SO, Oswald AE. Pregnancy and rheumatic disease: “by the book” or “by the doc. Clin Rheumatol. 2009;28(1):1–9. This article discusses drugs for rheumatic diseases that are allowed or not allowed in pregnancy.PubMedCrossRef

55.

Clowse ME. Lupus activity in pregnancy. Rheum Dis Clin North Am. 2007;33(2):237–52. v.PubMedCrossRef

56.

Petri M. The Hopkins Lupus Pregnancy Center: ten key issues in management. Rheum Dis Clin North Am. 2007;33(2):227–35. v.PubMedCrossRef

57.

•• Branch W. Report of the Obstetric APS Task Force: 13th International Congress on Antiphospholipid Antibodies, 13th April 2010. Lupus. 2011;20(2):158–64. This article provides the opinions of experts in obstetric APS from the last congress of APS held in Galveston, TX.PubMedCrossRef

58.

Duhl AJ, Paidas MJ, Ural SH, et al. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol. 2007;197(5):457 e1–21.CrossRef

59.

Khamashta MA. Systemic lupus erythematosus and pregnancy. Best Pract Res Clin Rheumatol. 2006;20(4):685–94.PubMedCrossRef

60.

Ruiz-Irastorza G, Khamashta MA, Nelson-Piercy C, Hughes GR. Lupus pregnancy: is heparin a risk factor for osteoporosis? Lupus. 2001;10(9):597–600.PubMedCrossRef

61.

Erkan D, Yazici Y, Peterson MG, et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford). 2002;41(8):924–9.CrossRef

62.

•• Rand JH, Wu XX, Quinn AS, Taatjes DJ. The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus. 2010;19(4):460–9. This is a very interesting and original paper showing how the aPL-mediated reduction of annexin A5, a potent anticoagulant that shields phospholipid layers on placental villi, is responsible for fetal loss and thrombosis in APS animal models, and showing that HCQ can revert these aPL complexes, also helping in the formation of “patches” of annexin A5.PubMedCrossRef

63.

• Pierangeli SS, Erkan D. Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? Lupus. 2010;19(4):475–85. This article considers new pathways of APS and how new treatments are targeted.PubMedCrossRef

64.

• Galanis T, Thomson L, Palladino M, Merli GJ. New oral anticoagulants. J Thromb Thrombolysis. 2011;31(3):310–20. This article discusses the pharmacokinetics of the new anticoagulants.PubMedCrossRef

65.

• Cohen H, Machin SJ. Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? Lupus. 2010;19(4):486–91. This article discusses the role of the new anticoagulants in patients with APS; it was written by the group that pioneered the trials on these new products.PubMedCrossRef

Title: Management of Obstetric Antiphospholipid Syndrome
Authors: Guilherme Ribeiro Ramires de Jesus
Flavia Cunha dos Santos
Camila Souto Oliveira
Wallace Mendes-Silva
Nilson Ramires de Jesus
Roger Abramino Levy
Publication date: 01-02-2012
Publisher: Current Science Inc.
Published in: Current Rheumatology Reports / Issue 1/2012
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-011-0218-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2012

Scleroderma Mimics

Laboratory Diagnosis of the Lupus Anticoagulant

Drug-Induced Lupus Anticoagulants and Antiphospholipid Antibodies

Genetics of Systemic Sclerosis: An Update

Application of Biomarkers to Clinical Trials in Systemic Sclerosis

An Update on the Evaluation and Management of Pulmonary Hypertension in Scleroderma

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials